Deutsche Bank Upgrades Roche to 'Buy'

Deutsche Bank has upgraded Roche's stock rating to 'Buy' based on favorable feedback from physicians regarding the oncology drug Giredestrant, as noted by analyst Emmanuel Papadakis. The upgrade reflects a reduction in immediate risks associated with the drug and aligns with market consensus, suggesting positive implications for Roche's short- and medium-term outlook.